139 related articles for article (PubMed ID: 2179640)
21. Idarubicin: an anthracycline antineoplastic agent.
Cersosimo RJ
Clin Pharm; 1992 Feb; 11(2):152-67. PubMed ID: 1551297
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic comparison of 120-hour infusion versus hyperfractionated oral administration of idarubicin.
Toffoli G; Sorio R; Basso B; Aita P; Corona G; Rupolo M; Boiocchi M
J Chemother; 2004 Apr; 16(2):193-200. PubMed ID: 15216956
[TBL] [Abstract][Full Text] [Related]
23. High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Bengala C; Danesi R; Guarneri V; Pazzagli I; Donati S; Favre C; Fogli S; Biadi O; Innocenti F; Del Tacca M; Mariani M; Conte PF
Bone Marrow Transplant; 2003 Feb; 31(4):275-80. PubMed ID: 12621462
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.
Gillies HC; Herriott D; Liang R; Ohashi K; Rogers HJ; Harper PG
Br J Clin Pharmacol; 1987 Mar; 23(3):303-10. PubMed ID: 3471265
[TBL] [Abstract][Full Text] [Related]
25. [Oral idarubicin in treatment of advanced breast carcinoma].
Kerpel-Fronius S; Heinisch H
Zentralbl Gynakol; 1996; 118(10):587-9. PubMed ID: 8999720
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats.
Zara GP; Bargoni A; Cavalli R; Fundarò A; Vighetto D; Gasco MR
J Pharm Sci; 2002 May; 91(5):1324-33. PubMed ID: 11977108
[TBL] [Abstract][Full Text] [Related]
27. Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies.
Speth PA; Minderman H; Haanen C
Semin Oncol; 1989 Feb; 16(1 Suppl 2):2-9. PubMed ID: 2648580
[No Abstract] [Full Text] [Related]
28. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells.
Tidefelt U; Prenkert M; Paul C
Cancer Chemother Pharmacol; 1996; 38(5):476-80. PubMed ID: 8765443
[TBL] [Abstract][Full Text] [Related]
29. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.
Ruutu T; Almqvist A; Hallman H; Honkanen T; Järvenpää E; Järventie G; Koistinen P; Koivunen E; Lahtinen R; Lehtinen M
Leukemia; 1994 Jan; 8(1):11-5. PubMed ID: 8289475
[TBL] [Abstract][Full Text] [Related]
30. Plasma pharmacokinetics of Idarubicin and its 13-hydroxymetabolite after intravenous and oral administration under fasting and non-fasting conditions.
Eksborg S; Söderberg M; Nilsson B; Antila K
Acta Oncol; 1990; 29(7):921-5. PubMed ID: 2261209
[TBL] [Abstract][Full Text] [Related]
31. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent.
Muus P; Donnelly P; Schattenberg A; Linssen P; Minderman H; Dompeling E; de Witte T
Semin Oncol; 1993 Dec; 20(6 Suppl 8):47-52. PubMed ID: 8290971
[TBL] [Abstract][Full Text] [Related]
32. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.
Ganzina F; Pacciarini MA; Di Pietro N
Invest New Drugs; 1986; 4(1):85-105. PubMed ID: 3516918
[TBL] [Abstract][Full Text] [Related]
33. Determination of idarubicin and idarubicinol in plasma by capillary electrophoresis.
Hempel G; Haberland S; Schulze-Westhoff P; Möhling N; Blaschke G; Boos J
J Chromatogr B Biomed Sci Appl; 1997 Sep; 698(1-2):287-92. PubMed ID: 9367219
[TBL] [Abstract][Full Text] [Related]
34. [Antineoplastic effectiveness and toxicity of idarubicin (4-demethoxy-daunorubicin) in recurrent acute leukemias in childhood].
Erttmann R; Bode U; Erb N; Forcadell de Dios P; Gutjahr P; Haas R; Kuhn N; Siewert H; Landbeck G
Klin Padiatr; 1988; 200(3):200-4. PubMed ID: 3062256
[TBL] [Abstract][Full Text] [Related]
35. [Early phase II study of Idarubicin, a new anthracycline anticancer drug, in acute leukemia. Idarubicin Study Group].
Ogawa M; Masaoka T; Yamada K; Kimura K
Gan To Kagaku Ryoho; 1993 May; 20(7):897-906. PubMed ID: 8489296
[TBL] [Abstract][Full Text] [Related]
36. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y
Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
[TBL] [Abstract][Full Text] [Related]
37. [Pharmacokinetics of new anthracyclines].
Robert J
Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
[TBL] [Abstract][Full Text] [Related]
38. A review of idarubicin in acute leukemia.
Berman E
Oncology (Williston Park); 1993 Oct; 7(10):91-8, 104; discussion 104-7. PubMed ID: 8251309
[TBL] [Abstract][Full Text] [Related]
39. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
[TBL] [Abstract][Full Text] [Related]
40. Idarubicin in acute leukemia: results of US trials.
Berman E; Raymond V; Gee TS; Kempin SJ; Gulati S; Andreeff M; Gabrilove J; Young CW; Clarkson BD; Wiernik PH
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():49. PubMed ID: 2713561
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
